{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T15:36:23Z","timestamp":1783092983304,"version":"3.54.6"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,20]]},"DOI":"10.7759\/cureus.79378","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T20:15:37Z","timestamp":1740082537000},"source":"Crossref","is-referenced-by-count":4,"title":["Effectiveness of Atomoxetine and Stimulant Combination in Attention-Deficit\/Hyperactivity Disorder (ADHD) Treatment: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Tom","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J","family":"Boileau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425787","article-title":"Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR)","author":"American Psychiatric Association","year":"2022","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). American Psychiatric Association Publishing, Washington, DC; 2022. 10.1176\/appi.books.9780890425787"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)33004-1","article-title":"Attention-deficit hyperactivity disorder","volume":"395","author":"Posner J","year":"2020","unstructured":"Posner J, Polanczyk GV, Sonuga-Barke E. Attention-deficit hyperactivity disorder. Lancet. 2020, 395:450-62. 10.1016\/S0140-6736(19)33004-1","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-020-00998-0","article-title":"Global economic burden of attention-deficit\/hyperactivity disorder: a systematic review","volume":"39","author":"Chhibber A","year":"2021","unstructured":"Chhibber A, Watanabe AH, Chaisai C, Veettil SK, Chaiyakunapruk N. Global economic burden of attention-deficit\/hyperactivity disorder: a systematic review. Pharmacoeconomics. 2021, 39:399-420. 10.1007\/s40273-020-00998-0","journal-title":"Pharmacoeconomics"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.5863\/1551-6776-21.3.192","article-title":"A review of pharmacological management of attention-deficit\/hyperactivity disorder","volume":"21","author":"Briars L","year":"2016","unstructured":"Briars L, Todd T. A review of pharmacological management of attention-deficit\/hyperactivity disorder. J Pediatr Pharmacol Ther. 2016, 21:192-206. 10.5863\/1551-6776-21.3.192","journal-title":"J Pediatr Pharmacol Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.21037\/tp.2017.08.02","article-title":"Pharmacologic management of attention deficit hyperactivity disorder in children and adolescents: a review for practitioners","volume":"7","author":"Brown KA","year":"2018","unstructured":"Brown KA, Samuel S, Patel DR. Pharmacologic management of attention deficit hyperactivity disorder in children and adolescents: a review for practitioners. Transl Pediatr. 2018, 7:36-47. 10.21037\/tp.2017.08.02","journal-title":"Transl Pediatr"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-018-0116-3","article-title":"Treatment strategies for ADHD: an evidence-based guide to select optimal treatment","volume":"24","author":"Caye A","year":"2019","unstructured":"Caye A, Swanson JM, Coghill D, Rohde LA. Treatment strategies for ADHD: an evidence-based guide to select optimal treatment. Mol Psychiatry. 2019, 24:390-408. 10.1038\/s41380-018-0116-3","journal-title":"Mol Psychiatry"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2015.0137","article-title":"Atomoxetine: a review of its pharmacokinetics and pharmacogenomics relative to drug disposition","volume":"26","author":"Yu G","year":"2016","unstructured":"Yu G, Li GF, Markowitz JS. Atomoxetine: a review of its pharmacokinetics and pharmacogenomics relative to drug disposition. J Child Adolesc Psychopharmacol. 2016, 26:314-26. 10.1089\/cap.2015.0137","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2012.0093","article-title":"A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit\/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability","volume":"23","author":"Treuer T","year":"2013","unstructured":"Treuer T, Gau SS, M\u00e9ndez L, et al.. A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit\/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability. J Child Adolesc Psychopharmacol. 2013, 23:179-93. 10.1089\/cap.2012.0093","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604.ch7","article-title":"Considering bias and conflicts of interest among the included studies","author":"Boutron I","year":"2019","unstructured":"Boutron I, Page MJ, Higgins JP, Altman DG, Lundh A, Hr\u00f3bjartsson A. Considering bias and conflicts of interest among the included studies. Cochrane Handbook for Systematic Reviews of Interventions, Second Edition. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (ed): Wiley, New York, NY; 2019. 177-204. 10.1002\/9781119536604.ch7"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604.ch14","article-title":"Completing \u2018summary of findings\u2019 tables and grading the certainty of the evidence","author":"Sch\u00fcnemann HJ","year":"2019","unstructured":"Sch\u00fcnemann HJ, Higgins JP, Vist GE, Glasziou P, Akl EA, Skoetz N, Guyatt GH. Completing \u2018summary of findings\u2019 tables and grading the certainty of the evidence. Cochrane Handbook for Systematic Reviews of Interventions, Second Edition. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (ed): Wiley, New York, NY; 2019. 375-402. 10.1002\/9781119536604.ch14"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2006.01.011","article-title":"A simple and valid tool distinguished efficacy from effectiveness studies","volume":"59","author":"Gartlehner G","year":"2006","unstructured":"Gartlehner G, Hansen RA, Nissman D, Lohr KN, Carey TS. A simple and valid tool distinguished efficacy from effectiveness studies. J Clin Epidemiol. 2006, 59:1040-8. 10.1016\/j.jclinepi.2006.01.011","journal-title":"J Clin Epidemiol"},{"key":"ref13","article-title":"The Clinical Global Impressions scale: applying a research tool in clinical practice","volume":"4","author":"Busner J","year":"2007","unstructured":"Busner J, Targum SD. The Clinical Global Impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007, 4:28-37.","journal-title":"Psychiatry (Edgmont)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.9758\/cpn.2021.19.4.705","article-title":"Combined medication with stimulants and non-stimulants for attention-deficit\/hyperactivity disorder","volume":"19","author":"Bahn GH","year":"2021","unstructured":"Bahn GH, Seo K. Combined medication with stimulants and non-stimulants for attention-deficit\/hyperactivity disorder. Clin Psychopharmacol Neurosci. 2021, 19:705-11. 10.9758\/cpn.2021.19.4.705","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.2015.1102060","article-title":"Atomoxetine monotherapy compared with combination therapy for the treatment of ADHD: a retrospective chart review study","volume":"15","author":"Clemow DB","year":"2015","unstructured":"Clemow DB, Mason OW, Sarkis EH, et al.. Atomoxetine monotherapy compared with combination therapy for the treatment of ADHD: a retrospective chart review study. Expert Rev Neurother. 2015, 15:1353-66. 10.1586\/14737175.2015.1102060","journal-title":"Expert Rev Neurother"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/cns.12595","article-title":"Clinical impact of not achieving recommended dose on duration of atomoxetine treatment in adults with attention-deficit\/hyperactivity disorder","volume":"22","author":"Clemow DB","year":"2016","unstructured":"Clemow DB, Nyhuis AW, Robinson RL. Clinical impact of not achieving recommended dose on duration of atomoxetine treatment in adults with attention-deficit\/hyperactivity disorder. CNS Neurosci Ther. 2016, 22:970-8. 10.1111\/cns.12595","journal-title":"CNS Neurosci Ther"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-81416-z","article-title":"Risk factors for low adherence to methylphenidate treatment in pediatric patients with attention-deficit\/hyperactivity disorder","volume":"11","author":"Ishizuya A","year":"2021","unstructured":"Ishizuya A, Enomoto M, Tachimori H, Takahashi H, Sugihara G, Kitamura S, Mishima K. Risk factors for low adherence to methylphenidate treatment in pediatric patients with attention-deficit\/hyperactivity disorder. Sci Rep. 2021, 11:1707. 10.1038\/s41598-021-81416-z","journal-title":"Sci Rep"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3109\/15622975.2015.1051109","article-title":"Combined methylphenidate and atomoxetine pharmacotherapy in attention deficit hyperactivity disorder","volume":"16","author":"Ozbaran B","year":"2015","unstructured":"Ozbaran B, Kose S, Yuzuguldu O, Atar B, Aydin C. Combined methylphenidate and atomoxetine pharmacotherapy in attention deficit hyperactivity disorder. World J Biol Psychiatry. 2015, 16:619-24. 10.3109\/15622975.2015.1051109","journal-title":"World J Biol Psychiatry"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.5765\/jkacap.230048","article-title":"Effectiveness and tolerability of combination pharmacotherapy with stimulant and non-stimulant in children with attention deficit hyperactivity disorder","volume":"35","author":"Park HN","year":"2024","unstructured":"Park HN, Kong NY, Kim HC, Kim YT, Jung SW, Lee H. Effectiveness and tolerability of combination pharmacotherapy with stimulant and non-stimulant in children with attention deficit hyperactivity disorder. J Korean Acad Child Adolesc Psychiatry. 2024, 35:82-9. 10.5765\/jkacap.230048","journal-title":"J Korean Acad Child Adolesc Psychiatry"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/326373-effectiveness-of-atomoxetine-and-stimulant-combination-in-attention-deficithyperactivity-disorder-adhd-treatment-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T20:15:38Z","timestamp":1740082538000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/326373-effectiveness-of-atomoxetine-and-stimulant-combination-in-attention-deficithyperactivity-disorder-adhd-treatment-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.79378","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,20]]}}}